Reviews/Ssris and Snris/SSRIs are safe and reduce depression in patients after myocardial infarction
· SS-SPC-02 · v2
The claim has two parts: that these antidepressants are safe after a heart attack and that they ease depression. On safety, the main trial [5] found no harm to heart pumping function and fewer severe heart complications than placebo, and a large real-world study [7] linked their use to lower death rates, though with more serious bleeding. On depression, the same trial's main measuring scale did not show a clear benefit for everyone, with improvement showing up mainly on a second scale and in the more severely or repeatedly depressed patients. Other real-world data point the opposite way on safety, linking the drugs to more heart events [17] and, at high doses of certain drugs, to cardiac arrest [15]. Because the strong trial evidence covers one drug (sertraline) rather than the whole class, and the depression benefit is modest, the panel treated the combined claim as only partly carried.
The pivotal randomised trial [5] found sertraline had no significant effect on left ventricular ejection fraction and a lower incidence of severe cardiovascular adverse events (14.5% with sertraline vs 22.4% with placebo), but its primary depression scale was non-significant in the total sample (HAM-D P=.14) while the CGI-I favoured sertraline (P=.049; 67% vs 53% responders, P=.01). A large STEMI cohort [7] of 22,427 patients linked baseline SSRI use to lower all-cause mortality without excess recurrent MI or stroke, but with more major bleeding at 3 years. Supportive signals come from faster SDNN recovery in a small post-MI trial [2] and antiplatelet biomarker correlations in a SADHART substudy [1]. Countervailing data associate SSRIs with more MACE in coronary artery disease (HR 1.45, CI 1.07-1.97) [17] and high-dose citalopram/escitalopram with out-of-hospital cardiac arrest [15], while [16] found no excess sudden cardiac death for SSRIs (RR 0.95). The contested point: The division is sharpest on whether 'safe' and 'reduce depression' both hold: trial safety data [5] and cohort mortality [7] support the safety arm, yet observational MACE [17] and high-dose arrhythmia [15] signals qualify it, and the depression arm rests on a null primary endpoint with benefit confined to CGI-I and severe/recurrent subgroups [5].
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The efficacy half overreaches: the pivotal RCT's primary depression measure (HAM-D) was non-significant in the total sample (P=.14); benefit rested on the secondary CGI-I and pre-specified severe/recurrent subgroups, so 'reduce depression' is stronger than the primary endpoint supports.
'Safe' is not unqualified — [17] associates SSRIs with more MACE (HR 1.45, CI 1.07-1.97) in CAD, [7] shows excess major bleeding at 3 years, and [15] shows dose-dependent OHCA risk for high-dose citalopram/escitalopram.
Where it remains uncertain. The trial's primary depression endpoint was null (HAM-D P=.14) with benefit only on CGI-I and subgroups [5], while observational data link SSRIs to more MACE (HR 1.45) [17] and high-dose arrhythmia risk [15].
Aleatory
The in-population randomised evidence beyond the pivotal trial is small (e.g. N=38 in [2]), so random variation dominates secondary and surrogate endpoints.
Epistemic
Adequately-powered RCT data are for sertraline [5]; whether other SSRIs share its post-MI safety and efficacy profile is not established, and [15] shows intra-class differences.
Inferential
The main post-MI safety cohort [7] measures baseline/prevalent SSRI use, not treatment initiated after MI, so healthy-adherer and immortal-time bias may drive the mortality association; authors concede residual confounding.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Mechanistic basis for antiplatelet effect, relevant to both safety and bleeding.
“This is the first documented evidence that plasma release of platelet/endothelial biomarkers is directly related to the levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression.”
Panel auditInternal validity: medium · scope of inference: Biomarker/pharmacokinetic relationship in 55 acute coronary syndrome patients with depression treated with sertraline.Key limitations: surrogate biomarker endpoints only · very small sample · no clinical safety or depression outcome · authors call for an RCT to assess clinical significance
In-population RCT showing a favourable surrogate (autonomic) effect.
“In depressed patients who have survived the acute phase of an MI sertraline facilitates the rate of recovery of SDNN, a recognized predictor of clinical outcome.”
Panel auditInternal validity: medium · scope of inference: Effect of sertraline on cardiac autonomic recovery in depressed survivors of acute MI.Key limitations: surrogate HRV endpoint, not depression or safety · small sample · short-term power spectral indices did not reach significance
Pivotal RCT conclusion supporting both arms of the claim for sertraline specifically.
“In the total randomized sample, the CGI-I (P =.049), but not the HAM-D (P =.14), favored sertraline.”
Panel auditInternal validity: high · scope of inference: Sertraline for major depression in patients hospitalised for acute MI or unstable angina without other life-threatening illness.Key limitations: HAM-D not significant in total randomised sample (P=.14) · efficacy strongest in recurrent/severe subgroups · single SSRI (sertraline) · excludes other life-threatening conditions
Observational safety signal — SSRIs associated with more MACE in cardiac patients, counterweight to 'safe'.
“those on SSRI (HR = 1.45; 95% CI 1.07-1.97)”
Panel auditInternal validity: medium · scope of inference: Association of antidepressant class with depressive symptoms and MACE in cardiac-rehab CAD patients.Key limitations: observational, confounding by indication · CAD/rehab population, not only post-MI · depression benefit vs safety harm point opposite ways
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Safety is reasonably supported for sertraline but qualified by bleeding and MACE signals, and the efficacy arm rests on a null primary endpoint with only subgroup benefit, so the combined claim lands as Uncertain rather than Likely.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Class-wide RCT in post-MI patients. RCT-grade evidence is confined to sertraline [5]; the claim is about SSRIs as a class, and [15] shows meaningful intra-class safety differences. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled trial of a non-sertraline SSRI in recent-MI patients with MDD, powered on both depression and cardiovascular endpoints.
Open question: Does an SSRI other than sertraline provide the same safety and depression benefit after recent MI? Why it is still open: All adequately-powered RCT evidence in the corpus is for sertraline [5]; [15] shows intra-class differences in cardiac-arrest risk.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19